A Multicenter, Open Study to Evaluate the Long-term Safety and Efficacy of TPN171H in Patients with Erectile Dysfunction
Latest Information Update: 11 Jun 2025
At a glance
- Drugs Simmerafil (Primary)
- Indications Erectile dysfunction
- Focus Adverse reactions; Registrational
- Sponsors Vigonvita Life Sciences
Most Recent Events
- 05 Jun 2025 Planned End Date changed from 30 Apr 2025 to 30 Aug 2025.
- 05 Jun 2025 Planned primary completion date changed from 30 Apr 2025 to 30 Aug 2025.
- 24 Oct 2024 Planned number of patients changed from 400 to 472.